Lymphangiogenesis and Lymphatic Metastasis in Breast Cancer

Panel 1: Inflammation, hypoxia and reactive oxygen species (ROS) up-regulate expression of pro-lymphangiogenic factors VEGF-C, VEGF-D and VEGF-A produced by both tumor neoplastic and tumor-associated stromal cells (e.g. macrophages and fibroblasts). Panel 2: New lymphatic vessels are formed mainly in the peritumoral region but in some cases also intratumorally. The formation of new lymphatic vessels involves activation of VEGFR-3 by VEGF-C/-D and VEGFR-2 by VEGF-A as well as mature forms of VEGF-C/-D. Following, LEC proliferate, migrate and assemble into new vessels. The process may include incorporation of tumor-recruited circulating LEC progenitor cells. Panel 3: Tumor cells might actively invade intratumoral or peritumoral lymphatic vessels, or might be passively encapsulated by lymphatic vessels. Both types of interactions promote LVI leading to lymphatic metastasis to the sentinel lymph node. The active metastasis includes chemotactic recruitment of tumor cells expressing CCR7 or CXCR4 receptors by corresponding chemokines (CCL21 and SDF-1) expressed by the local lymphatic system. Panel 4: Unknown tumor-secreted factors that may include, but not limited to VEGF-A and VEGF-C, elicit profound morphological changes in the sentinel LN culminating in lymph node lymphangiogenesis (LNL) and lymphatic hypertrophy. Dramatically increased lymph flow in and out of the sLN promotes both lymphatic metastasis and further dissemination to distant organs. Panel 5: The pathway to distant organs may occur through both blood and lymphatic vasculature. Following dissemination through lymphatic vessels to the sentinel LN, tumor cells may enter the blood circulation through nodal blood vessels, or proceed with the lymphatic flow and enter the venous circulation via the thoracic duct, both pathways leading to distant organ metastasis.
Lymphangiogenesis and Lymphatic Metastasis in Breast Cancer

Publication

Lymphangiogenesis and Lymphatic Metastasis in Breast Cancer. () Sophia Ran, et al. Pathophysiology. ;17(4):229-251. Figure: F2.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates VEGF-C VEGFC ncbigene_symbol VEGFC 7424
Homo sapiens Primates VEGF-D VEGF-D ncbigene_synonym VEGFD 2277
Homo sapiens Primates LEC LEC ncbigene_synonym CCL16 6360
Homo sapiens Primates VEGF-A VEGFA ncbigene_symbol VEGFA 7422
Homo sapiens Primates VEGFR-3 VEGFR-3 ncbigene_synonym FLT4 2324
Homo sapiens Primates VEGFR-2 VEGFR2 ncbigene_synonym KDR 3791
Homo sapiens Primates CCL21 CCL21 ncbigene_symbol CCL21 6366
Homo sapiens Primates SDF-1 SDF1 ncbigene_synonym CXCL12 6387
Homo sapiens Primates CCR7 CCR7 ncbigene_symbol CCR7 1236
Homo sapiens Primates CXCR4 CXCR4 ncbigene_symbol CXCR4 7852
Danio rerio Vertebrates VEGF-C VEGFC ncbigene_symbol vegfc 403049
Danio rerio Vertebrates VEGF-D VEGF-D ncbigene_synonym vegfd 678512
Danio rerio Vertebrates VEGF-A VEGFA ncbigene_synonym vegfaa 30682
Danio rerio Vertebrates VEGFR-3 VEGFR3 ncbigene_synonym flt4 30121
Danio rerio Vertebrates VEGFR-2 VEGFR-2 ncbigene_synonym kdrl 796537
Danio rerio Vertebrates SDF-1 SDF-1 ncbigene_synonym cxcl12a 352944
Danio rerio Vertebrates CCR7 CCR7 ncbigene_symbol ccr7 565958
Danio rerio Vertebrates CXCR4 CXCR4 ncbigene_synonym cxcr4b 114447

Chemical mentions

Word Match MeSH Name ChEBI

Disease mentions

Word Match MeSH Name DOID